Evidence map›Paper›PMID 41206392›Full record

ReviewDiabetologia2026

Is the NOD mouse a good model for type 1 diabetes?

F Susan Wong, James A Pearson, Li Wen

Abstract readReview
In one paragraph

Review in Diabetologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

F Susan WongDiabetes Research Group, Division of Infection and Immunity, Systems Immunity University Research Institute, Cardiff University School of Medicine, Cardiff University, Cardiff, UK. wongfs@cardiff.ac.uk.ORCID 0000-0002-2812-8845
James A PearsonDiabetes Research Group, Division of Infection and Immunity, Systems Immunity University Research Institute, Cardiff University School of Medicine, Cardiff University, Cardiff, UK.ORCID 0000-0002-2867-2269
Li WenSection of Endocrinology, Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA.ORCID 0000-0002-8805-2934

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The NOD mouse is the best-known, although by no means the only, murine model of type 1 diabetes. In this review, we provide a historical perspective, particularly highlighting areas of progress in understanding aspects of aetiology and immune pathogenesis, and utility in helping to shape the immunotherapeutic landscape. We introduce points of interest where the NOD mouse, a much-studied model, has signposted discovery and knowledge. We discuss genetics, pancreatic islet beta cell stress, innate and adaptive immunity and autoantigens, and also focus on immunotherapeutic agents that have been tested in NOD mice and in humans. Some therapies, particularly those that are non-antigen-specific, have been more effectively signposted, while others, which include antigen-specific therapies, have not. There is an inevitable divergence between mice and humans that illustrates the need to use models appropriately. We suggest how to make use of this and other models effectively in order to maximise information and knowledge, and suggest not dismissing this important resource because of inappropriate comparisons or unrealistic expectations.

Indexed as

Diabetes Mellitus, Type 1Disease Models, AnimalAnimalsAutoantigensHumansImmunotherapyInsulin-Secreting CellsMiceMice, Inbred NODAutoantigensImmunotherapyNOD mousePathogenesisReviewType 1 diabetes

Identifiers

PMID41206392
PMCPMC12686005

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.